Merkel Cell Carcinoma clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a First-in-Human Phase IA/IB open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Davis, California and other locations